Low-dose Combination of Three Antihypertensive Drugs

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT02710552

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02710552
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02710552. Randomized; single masking; primary purpose treatment. Start 2016-04 (registry gives no type); primary completion 2019-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Low-dose Combination of Three Antihypertensive Drugs
Acronym
3D
Condition
Arterial Hypertension
Intervention (Drug)
Tripliam (perindopril, indapamide, amlodipine)
Intervention (Drug)
Reaptan (perindopril, amlodipine)
Lead sponsor
University of Roma La Sapienza (class: other)

Record details

Record id
cardio:ct-nct02710552
Content hash
66385b77f66c3480338d8cee8098381c170b210802cb76f4b795bb89b189b3d7